Ass. Prof. Dr. Karl Matz

ASPIS Study Group (2018). Multidomain intervention for the prevention of cognitive decline after stroke - a pooled patient-level data analysis. Eur J Neurol., 25: 1182-1188

Brainin, M.; Feigin, V.; Martins, S.; Matz, K.; Roy, J.; Sandercock, P.; Teuschl, Y.; Tuomilehto, J.; Wiseman, A. (2018). Cut stroke in half: Polypill for primary prevention in stroke. Int J Stroke, 25: 633-647

Matz, K. (2018). Frühe Thrombolyse von Schlaganfällen. neurologisch, 03: 87

Teuschl, Y.; Trapl, M:, Ratajczak, P.; Matz, K.; Dachenhausen, A.; Brainin, M. (2018). Systematic dysphagia screening and dietary modifications to reduce stroke-associated pneumonia rates in a stroke-unit. PLoS One, :e0192142: 10.1007/s00415-017-8720-8.

Mijajlovic, M.D.; Pavlovic, A.; Brainin, M.; Heiss, W.D.; Quinn, T.J.; Ihle-Hansen, H.B.; Hermann, D.M.; Assayag, E.B.; Richard, E.; Thiel, A.; Kliper, E.; Shin, Y.I.; Kim, Y.H.; Choi, S.; Jung, S.; Lee, Y.B.; Sinanovic, O.; Levine, D.A.; Schlesinger, I.; Mead, G.; Miloševic, V.; Leys, D.; Hagberg, G.; Ursin, M.H.; Teuschl, Y.; Prokopenko, S.; Mozheyko, E.; Bezdenezhnykh, A.; Matz, K.; et al. (2017). Post-stroke Dementia - a comprehensive review. BMC Medicine, 15(1):11: doi: 10.1186/s12916-017-0779-7

Teuschl, Y.; Matz, K.; Firlinger, B.; Dachenhausen, A.; Tuomilehto, J.; Brainin, M.; ASPIS Study Group. (2017). Preventive effects of multiple domain interventions on lifestyle and risk factor changes in stroke survivors: Evidence from a two-year randomized trial. International Journal of Stroke, 12(9): 976-984

Trapl, M.; Teuschl, Y.; Matz, K.; Dachenhausen, A.; Brainin, M. (2017). Overestimating the risk of aspiration in acute stroke. European Journal of Neurology, 24(6): doi:10.1111/ene.13298

Brainin, M.; Matz, K.; Nemec, M.; Teuschl, Y.; Dachenhausen, A.; Asenbaum-Nan, S.; Bancher, C.; Kepplinger B.; Oberndorfer, S.; Pinter, M.;, Schnider, P.; Tuomilehto, J.; ASPIS StudyGroup (2015). Prevention of poststroke cognitive decline: ASPIS - a multicenter,randomized, observer-blind, parallel group clinical trial to evaluate multiplelifestyle interventions - study design and baseline characteristics. International Journal of Stroke, 10(4): 627-35

Matz K.; Teuschl, Y.; Firlinger, B.; Dachenhausen, A.; Keindl, M.; Seyfang, L.; Tuomilehto, J.; Brainin, M. (2015). Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke Randomized Trial. Stroke, 46(10): 2874-80

IST-3 collaborative group (2013). Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International StrokeTrial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol, 12(8): 768-76

Matz, K.; Brainin, M. (2013). Use of Intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues. Expert Rev Neurother, 13(2): 177-185

Teuschl, Y.; Brainin, M.; Matz, K.; Ferrari, J.; Lang, W. (2013). Time-trends in patient characteristics treated upon acute stroke units: Results from the Austrian Stroke Unit Registry 2003 – 2011. Stroke, 44(4): 1070-4

Teuschl, Y.; Matz, K.; Brainin, M. (2013). Prevention of post-stroke cognitive decline: a review focusing on lifestyle interventions. Eur J Neurol. 2013, 20(1): 35-49

IST-3 collaborative group (u.a. Brainin, M.), Sandercock, P.; Wardlaw, J.M.; Lindley, R.I.; Dennis, M.; Cohen, G.; Murray, G.; Innes, K.; Venables, G.; Czlonkowska, A.; Kobayashi, A.; Ricci, S.; Murray, V.; Berge, E.; Slot, K.B.; Hankey, G.J.; Correia, M.; Peeters, A.; Matz, K.; Lyrer, P.; Gubitz, G.; Phillips, S.J.; Arauz, A. (2012). The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, 379(9834): 2352-63

Reiter, M.; Brainin, M.; Teuschl, Y.; Matz, K.; Seyfang, L.; Reindl, B. (2012). Thrombolysis in diabetic stroke patients: Results from the Austrian Stroke Unit Registry. Cerebrovasc Dis, 33 Suppl 2: 614-5

Teuschl, Y.; Matz, K.; Dachenhausen, A.; Tuomilehto, J.; Brainin, M. (2012). Factors associated with participation in a diabetes prevention program in Austria: a prospective cohort study . Diabetes Management, 2(5): 385-393

Reiner-Deitemyer, V.; Teuschl, Y.; Matz, K.; Reiter, M.; Eckhardt, R.; Seyfang, L.; Tatschl, C.; Brainin, M.; Austrian Stroke Unit Registry Collaborators. (2011). Helicopter Transport of Stroke Patients and Its Influence on Thrombolysis Rates. Data From the Austrian Stroke Unit Registry. Stroke, 42(5): 1295–1300

Sandercock, P.; Lindley, R.; Wardlaw, J.; Dennis, M.; Innes, K.; Cohen, G.; Whiteley, W.; Perry, D.; Soosay, V.; Buchanan, D.; Venables, G.; Czlonkowska, A.; Kobayashi, A.; Berge, E.; Slot, K.B.; Murray, V.; Peeters, A.; Hankey, G.J.; Matz, K.; Brainin, M.; Ricci, S.; Cantisani, T.A.; Gubitz, G.; Philli, S.J. (2011). Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited . Trials, 12(1): 252

Matz, K.; Brainin, M. (2010). Diabetes und Demenz. Typ-2-Diabetiker haben ein erhöhtes Demenzrisiko. Diabetes aktuell, 8 (6): 257 – 262

Brainin, M.; Matz, K. (2010). Typ-2-Diabetiker haben ein erhöhtes Demenzrisiko. Diabetes aktuell, 8(6): 257-262, Georg Thieme Verlag, Stuttgart